Search

Gene Sullivan, Chief Product Strategy Officer at Insmed, explores how new thinking could improve the research process for rare disease treatments

Our priorities paint a picture of who we are, and that’s as true in RNAi medicine development as it is elsewhere in life

An inside view on the French pharma company and Swiss NPO working on a treatment for a debilitating rare disease

UICC CEO Cary Adams gives his insights into the challenges of getting cancer treatment to people in low- and middle-income countries.

Applied correctly, data can do almost anything

It’s a fact that the pharma industry is dominated by white men. What does this mean for people from different ethnic backgrounds?

In the face of war and the economic fallout of COVID-19, Europe is weathering an energy price storm. What does this mean for medicine makers?

What can cell and gene do to avoid a seemingly inevitable rush on supporting products and services?

Two drugs, two different destinies. Does their story prove that business practice makes the difference?

Sitting Down With… Tunde Bello, Vice President of Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, New Jersey, USA.